Titan Pharmaceuticals (NASDAQ:TTNP) will post its Q1 quarterly earnings results after the market closes on Wednesday, May 15th. Analysts expect Titan Pharmaceuticals to post earnings of ($0.26) per share for the quarter.
Titan Pharmaceuticals (NASDAQ:TTNP) last released its quarterly earnings results on Monday, April 1st. The specialty pharmaceutical company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.20). The business had revenue of $1.24 million for the quarter, compared to analysts’ expectations of $0.40 million. Titan Pharmaceuticals had a negative return on equity of 355.20% and a negative net margin of 136.32%. On average, analysts expect Titan Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NASDAQ TTNP opened at $1.62 on Tuesday. The firm has a market cap of $22.78 million, a PE ratio of -2.05 and a beta of 0.67. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.85 and a quick ratio of 3.49. Titan Pharmaceuticals has a twelve month low of $1.03 and a twelve month high of $6.90.
Separately, ValuEngine upgraded Titan Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, February 2nd.
An institutional investor recently raised its position in Titan Pharmaceuticals stock. Geode Capital Management LLC lifted its holdings in shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) by 256.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 341,474 shares of the specialty pharmaceutical company’s stock after purchasing an additional 245,565 shares during the quarter. Geode Capital Management LLC owned about 2.63% of Titan Pharmaceuticals worth $76,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 24.17% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Macon Daily and is owned by of Macon Daily. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://macondaily.com/2019/05/14/titan-pharmaceuticals-ttnp-set-to-announce-quarterly-earnings-on-wednesday.html.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.
Featured Story: How do candlesticks reflect price movement?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.